From basic research to clinical results. OVERTURE, ENABLE, and RENEWAL studies;De la investigación básica a los resultados clínicos. Estudios OVERTURE, ENABLE y RENEWAL

Archivos de Cardiologia de Mexico

Volumn 73, Issue SUPPL. 1, 2003, Pages

  Pastelín Hernández, Gustavo ^a   Del Valle Mondragón, Leonardo ^a   Tenorio López, Fermín Alejandro ^a  

^a INSTITUTO NACIONAL DE CARDIOLOGÍA IGNACIO CHÁVEZ   (Mexico)

Author keywords

Angiotensin II; Cardiac failure; Endothelin; Tumoral necrosis factor

Indexed keywords

BOSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN RECEPTOR; ETANERCEPT; OMAPATRILAT; PROTEINASE; TUMOR NECROSIS FACTOR ALPHA;

CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HEART FAILURE; HUMAN; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOGLOBULIN G; PYRIDINES; RECEPTORS, TUMOR NECROSIS FACTOR; SULFONAMIDES; THIAZEPINES;

EID: 0042970450     PISSN: 14059940     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (7)

1. PACKER M, CALIFF RM, KONSTAM MA, KRUM H, MCMURRAY JJ, ROULEAU J-L, WEDBERG K: Comparison of omopatrilot and enalapril in patients with chronic heart failure: The Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events. Circulation 2002, 106: 920-926.
2. CORTI R, BURNETT J, ROULEAU J: Vasopeptidase inbibitors. A new therapeutic concept in cardiovascular disease? Circulation 2001; 104: 1856-1862.
3. ROULEAU J, PFEFFER M, STEWARD D: Comparison of the vasopeptidase inhibitor omapatrilat and lisinopril on excercise tolerance and morbility in patients with heart failure. IMPRESS randomized trial. Lancet 2000; 4: 85-92.
4. HURLIMANN D, ENSELEIT F, RODRIGUEZ H: Endothelin antagonists and heart failure. Curr Hypertens Rep 2002; 4: 85-92.
5. TAMARGO J, DELPON E: Futuro del tratamiento farmacológico de las enfermedades cardiovasculares. En: Bayés de Luna A, López-Sendón J, Attie F, Alegría Esquerra E: Cardiología clínica. Barcelona. Masson 2003, pp 861-882.
6. FELDMAN A, COMBES A, WAGNER D: The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000; 35: 537-544.
7. HERRERA E, HERRERA J, RODRÍGUEZ H: Importancia del factor de necrosis tumoral alfa en la patogenia de la insuficiencia cardíaca. Rev Esp Cardiol 2002; 55: 61-66.